🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are on the rise around the world, with figures suggesting more than 82 million infections each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the reality of rising global incidence, the spread of superbugs and the very limited therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Gain Authorization

Zoliflodacin, marketed under the name a brand name, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This approval represents a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Results and Global Access

Based on results detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which involves an injection and a pill. The study enrolled hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Clinicians treating patients have shared positive views. The availability of a one-pill regimen such as this is described as a "revolutionary step" for public health efforts. This is deemed vital to alleviate the strain of the disease for people and to stop the proliferation of untreatable gonorrhoea around the world.